For research use only. Not for therapeutic Use.
PD-156707 (Cat.No:I008612) is a chemical compound that acts as a selective antagonist of the adenosine A1 receptor. It has been investigated for its potential therapeutic applications in cardiovascular diseases and neurological disorders. PD-156707 exhibits inhibitory effects on adenosine-mediated signaling pathways and is under research for its pharmacological properties.
| Catalog Number | I008612 |
| CAS Number | 162412-70-6 |
| Synonyms | PD-156707; PD 156707; PD156707.;sodium (Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate |
| Molecular Formula | C28H25NaO9 |
| Purity | ≥95% |
| Target | Endothelin Receptor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | sodium;(Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate |
| InChI | InChI=1S/C28H26O9.Na/c1-32-19-8-5-17(6-9-19)26(29)20(11-16-12-23(33-2)27(35-4)24(13-16)34-3)25(28(30)31)18-7-10-21-22(14-18)37-15-36-21;/h5-10,12-14H,11,15H2,1-4H3,(H,30,31);/q;+1/p-1/b25-20-; |
| InChIKey | ZLHQEGFYBMZQGM-RKVLWQGQSA-M |
| SMILES | COC1=CC=C(C=C1)C(=O)C(=C(C2=CC3=C(C=C2)OCO3)C(=O)[O-])CC4=CC(=C(C(=C4)OC)OC)OC.[Na+] |
| Reference | </br>1:Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707-derived ET(A) receptor radioligands. Höltke C, Law MP, Wagner S, Breyholz HJ, Kopka K, Bremer C, Levkau B, Schober O, Schäfers M.Bioorg Med Chem. 2006 Mar 15;14(6):1910-7. Epub 2005 Nov 10. PMID: 16289856 </br>2:The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb. Coe Y, Haleen SJ, Welch KM, Liu YA, Coceani F.J Pharmacol Exp Ther. 2002 Aug;302(2):672-80. PMID: 12130731 Free Article</br>3:Discovery and development of an endothelin A receptor-selective antagonist PD 156707. Doherty AM, Uprichard AC.Pharm Biotechnol. 1998;11:81-112. Review. PMID: 9760677 </br>4:Effects of endothelin ETA receptor antagonism with PD 156707 on hemodynamics and renal vascular resistance in rabbits. Ignasiak DP, McClanahan TB, Saganek LJ, Potoczak RE, Hallak H, Gallagher KP.Eur J Pharmacol. 1997 Mar 5;321(3):295-300. PMID: 9085040 </br>5:Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs. Mertz TE, McClanahan TB, Flynn MA, Juneau P, Reynolds EE, Hallak H, Bradford L, Gallagher KP.J Pharmacol Exp Ther. 1996 Jul;278(1):42-9. PMID: 8764334 </br>6:Liquid chromatographic assay for a butenolide endothelin antagonist (PD 156707) in plasma. Rossi DT, Hallak H, Bradford L.J Chromatogr B Biomed Appl. 1996 Mar 3;677(2):299-304. PMID: 8704933 </br>7:Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist. Reynolds EE, Keiser JA, Haleen SJ, Walker DM, Olszewski B, Schroeder RL, Taylor DG, Hwang O, Welch KM, Flynn MA, et al.J Pharmacol Exp Ther. 1995 Jun;273(3):1410-7. PMID: 7791115 |
